logo

Zogenix, Inc. (ZGNX)



Trade ZGNX now with
  Date
  Headline
6/27/2019 8:15:22 AM Zogenix Announces FDA Agreement To Proceed With Resubmission Of FINTEPLA NDA
2/6/2019 8:10:24 AM Zogenix Submits NDA To FDA And MAA To European Medicines Agency For FINTEPLA For Dravet Syndrome
12/3/2018 9:23:18 AM Zogenix Reports Positive Phase 3 Trial Results On Efficacy, Safety Of FINTEPLA In Dravet Syndrome
8/30/2018 8:17:12 AM Zogenix Reports New Data On Impact Of Dravet Syndrome And Other Epileptic Encephalopathies
8/6/2018 5:15:06 PM Zogenix Intends To Offer And Sell 6 Mln Shares In Public Offering
7/12/2018 7:05:15 AM Zogenix Announces Positive Top-line Results From Second Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome
6/1/2018 4:38:00 PM Zogenix Reports Granting Of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4/25/2018 8:14:05 AM Zogeni Presents New Safety Data From First Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome
2/6/2018 8:06:57 AM Zogenix Reports Receipt Of FDA Breakthrough Therapy Designation For ZX008 In Dravet Syndrome